Arrowhead Pharmaceuticals investor relations material

Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of intractable diseases in the United States. Its two platform technology includes a subcutaneous gene therapy program, which is focused on developing RNAi candidates targeting RNA sequences that are not amenable to conventional oral delivery through compacted, double-stranded RNA formulations for liver targeted delivery; and peptide platform technology that enables subcutaneous delivery of biologically active oligonucleotide payloads without the need for liposomal or polymeric encapsulation systems.